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Abstract
Background: Prior to the availability of generic third-generation cephalosporins, penicillins were widely used for
treatment of pneumococcal meningitis in developing countries despite concerns about rising levels of penicillin
resistance among pneumococcal isolates. We examined the impact of penicillin resistance on outcomes of
pneumococcal meningitis over a ten year period in an infectious diseases hospital in Brazil.
Methods: Clinical presentation, antimicrobial therapy and outcomes were reviewed for 548 patients with culture-
confirmed pneumococcal meningitis from December, 1995, to November, 2005. Pneumococcal isolates from
meningitis patients were defined as penicillin-resistant if Minimum Inhibitory Concentrations for penicillin were
greater than 0.06 μg/ml. Proportional hazards regression was used to identify risk factors for fatal outcomes.
Results: During the ten-year period, ceftriaxone replaced ampicillin as first-line therapy for suspected bacterial
meningitis. In hospital case-fatality for pneumococcal meningitis was 37%. Of 548 pneumococcal isolates from
meningitis cases, 92 (17%) were resistant to penicillin. After controlling for age and severity of disease at admission,
penicillin resistance was associated with higher case-fatality (Hazard Ratio [HR], 1.62; 95% Confidence Interval [CI],
1.08-2.43). Penicillin-resistance remained associated with higher case-fatality when initial therapy included
ceftriaxone (HR, 1.68; 95% CI 1.02-2.76).
Conclusions: Findings support the use of third generation cephalosporin antibiotics for treatment of suspected
pneumococcal meningitis even at low prevalence of pneumococcal resistance to penicillins.
Background
Among bacterial causes of meningitis, Streptococcus
pneumoniae (the pneumococcus) is associated with the
highest case-fatality and is the most likely to leave survi-
vors with permanent sequelae. For the year 2000, the
WHO’s Global Burden of Disease project estimated
100,000 cases of pneumococcal meningitis occurred
among children <5 worldwide, with higher than 50%
case-fatality [1]. Over 95% of the pneumococcal deaths
occurred in developing countries.
Prior to the identification of penicillin-resistant pneu-
mococci, penicillin therapy was the standard treatment
for pneumococcal meningitis. Recommendations of the
American Academy of Pediatrics and Infectious Diseases
Society of America for first-line treatment of pneumo-
coccal meningitis were changed to a 3
rd generation
cephalosporin [2-4], following reports of treatment fail-
ure and pharmacokinetic studies showing inadequate
penicillin concentrations in the central nervous system to
treat penicillin-resistant pneumococcal infections. How-
ever, the substantial difference in cost of third generation
cephalosporins in the 1990s limited their use in develop-
ing countries. In 1997, the WHO recommended third
generation cephalosporins as the first-line treatment for
children ≥3 months of age with suspected bacterial
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phenicol and penicillin in developing countries [5], creat-
ing a double-standard [6-8]. The WHO recognized that
where “significant” pneumococcal resistance to penicillin
had been observed, cefotaxime or ceftriaxone were
recommended, while leaving individual countries to
determine what level of resistant would require a change
in first-line therapy. At the time of these recommenda-
tions, few data from developing countries were available
on the prevalence of penicillin-resistant pneumococci or
its clinical relevance. Following availability of generic cef-
triaxone after 1999, WHO recommended ceftriaxone
alone as first-line antibiotic therapy for suspected bacter-
ial meningitis in all countries [9]. However, despite avail-
ability of generic ceftriaxone, actual prices of this
antibiotic may remain high and limit its use for treatment
of pneumococcal meningitis in some developing coun-
tries [10].
To guide decisions about treatment of bacterial menin-
gitis at an infectious diseases referral hospital in Salvador,
Brazil, we established surveillance for penicillin-resistant
pneumococcal infections in December 1995. The identifi-
cation of penicillin resistance among 13% of pneumococ-
cal isolates from meningitis cases during the first three
years of surveillance led to a change in first-line antibiotic
treatment to ceftriaxone [11]. Because data are limited on
the clinical relevance of penicillin-resistance for out-
comes of pneumococcal meningitis, we analyzed data
from 10 years of surveillance for pneumococcal meningi-
tis cases before and after introduction of empiric ceftriax-
one therapy to investigate whether penicillin-resistance
was associated with case-fatality and adverse outcomes of
pneumococcal meningitis.
Methods
Patient population
Active hospital-based surveillance for bacterial meningitis
was established in 1996 at Couto Maia Hospital, the state
infectious diseases referral hospital in Salvador, Brazil
(estimated population in 2000 of 2,443,107 inhabitants)
[11]. The study protocol was approved by Institutional
Review Boards of Couto Maia Hospital and the Oswaldo
Cruz Foundation of the Brazilian Ministry of Health.
Patients with suspected meningitis in the metropolitan
region of Salvador were referred to Couto Maia hospital
for initial diagnostic evaluation, including lumbar puncture
and CSF analysis. After initial evaluation, patients were
admitted or transferred (4%) to another hospital. The sur-
veillance team reviewed the daily clinical laboratory record
at the infectious disease hospital to identify all patients
with an admission diagnosis of meningitis for whom
S. pneumoniae were isolated from cerebrospinal fluid
(CSF) or blood. Written informed consent was obtained
for all patients to perform medical chart review and data
collection. Antibiotic treatment decisions and use of sys-
temic corticosteroids were made by hospital staff.
We limited the analysis of factors associated with case-
fatality to pneumococcal meningitis cases with an isolate
from blood or CSF and complete antimicrobial susceptibil-
ity testing. We included only the first episode of pneumo-
coccal meningitis identified during the study period for 23
patients with recurrent episodes of pneumococcal menin-
gitis (21 with two episodes, one with three and one with
four). We also excluded three pneumococcal meningitis
episodes with onset of symptoms during hospitalization.
The analysis excludes 28 pneumococcal meningitis epi-
sodes (5 [18%] of which were caused by penicillin-resistant
pneumococci) in patients who were transferred and for
whom outcome was not known.
Clinical data collection and definitions
For all identified patients with pneumococcal meningitis
who were admitted to the surveillance hospital, a standar-
dized entry form was used to extract demographic and
clinical information from the medical records. Patients or
members of their immediate family were interviewed to
obtain information regarding duration of fever prior to
hospitalization. Previous antibiotic use was defined as the
use of any antibiotic in the previous month. Nosocomial
infection was defined as hospitalization >3 days before the
development of clinical symptoms of meningitis. Presence
of underlying medical conditions were obtained by medical
chart review or patient report and included AIDS, diabetes
mellitus, asplenia, sickle cell disease, immunodepression
and recurrent meningitis. Underlying conditions were
assumed to be absent if not recorded in medical records. If
not noted in clinical history or during physical examination
at admission, patients were assumed not to have presented
with seizures prior to admission or coma on admission.
Data were collected on antimicrobial treatment and cor-
ticosteroid use during hospitalization. According to Brazi-
lian Ministry of Health guidelines [12], empiric treatment
for suspected bacterial meningitis in patients 2 months to
5 years of age included ampicillin (200-400 mg/kg/24
hours) plus chloramphenicol (75-100 mg/kg/24 hours) or
ceftriaxone alone (100 mg/kg/24 hours); ampicillin or cef-
triaxone for patients older than 5 years; and ampicillin
plus an aminoglycoside (gentamycin or amykacin; 15 mg/
kg/24 hours), or cetriaxone plus ampicillin for infants less
than 2 months of age. When ampicillin was not available,
crystalline penicillin G (300,000 to 500,000 IU/kg every
4-6 h) was used in place of ampicillin. Antibiotic treatment
was initiated as soon as possible. Initial ampicillin therapy
was changed to ceftriaxone if the pneumococcal isolate
demonstrated resistance to penicillin. For pneumococcal
meningitis with reduced susceptibility to ceftriaxone,
vancomycin (60 mg/kg/24 hours) was added. Discordant
antibiotic therapy was defined as nonreceipt during the
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to which the isolated S. pneumoniae was susceptible.
Patients were considered to have received corticoster-
oids only if administration began within the first two
days of hospitalization. Sequelae were defined as pre-
sence at discharge of any neurological deficit, hearing
loss or sensory deficit, which required evaluation by a
neurologist or audiologist.
Laboratory methods and definitions
Methods for the identification, serotyping and antimicro-
bial susceptibility testing of pneumococcal isolates were
performed consistently throughout the study period as
previously described [13]. Patient isolates were screened
for reduced susceptibility to penicillin using a 1-ug oxa-
cillin disk and penicillin Etest strips [11,14]; results were
reported immediately to clinical staff. Minimal inhibitory
concentrations (MIC) were defined according to the
microdilution method as the lowest concentrations of
antibiotics that inhibited pneumococcal growth in vitro.
Microdilution trays were prepared according to the Clini-
cal and Laboratory Standards Institute (CLSI; formerly
the National Committee for Clinical Laboratory Stan-
dards) [15], including penicillin, chloramphenicol and
cefotaxime for resistance to third-generation cephalos-
porins. For consistency with revised CLSI susceptibility
breakpoints published in 2008 [15], we refer to pneumo-
coccal meningitis isolates with a MIC > 0.06 μg/ml as
penicillin-resistant (previously referred to as penicillin-
nonsusceptible). We refer to isolates with MIC > 1 μg/ml
as highly resistant to penicillins [15]. Resistance to chlor-
amphenicol was defined as MIC > 4 μg/ml. Intermediate
resistance to ceftriaxone was defined as MIC equal to 1
μg/ml.
Statistical Analysis
A database of laboratory information was created and
analyzed in Epi-Info, version 3.2 (Centers for Diseases
Control and prevention, Atlanta, USA). Proportions of S.
pneumoniae serotypes or nontypeable strains isolated
from CSF or blood culture were compared with the c
2
test with Yates’ correction. We considered duration of
symptoms prior to hospitalization, convulsions prior to
admission, blood leukocyte count, CSF protein and glu-
cose concentrations and presence of coma as potential
markers of disease severity at admission. Generalized
additive models (GAM) were used to determine thresh-
old values to create dichotomous variables for blood leu-
kocyte count, CSF protein and glucose. The association
between covariates and the rate of death was analyzed in
Cox proportional hazard regression models including age
strata, gender and variables significantly associated with
death in univariate analyses. Backward selection was used
to identify a final model including the minimal set of
statistically significant (p < 0.05) variables. We evaluated
possible effect modification by age category by perform-
ing stratified multivariable analyses for patients <15 years
versus those 15 years or older, and for patients initially
treated with ceftriaxone versus those whose initial anti-
biotic therapy did not include ceftriaxone. All multivari-
ate analyses were performed with R software (version
2.11.1; available at http://www.r-project.org).
Results
We included 548 pneumococcal meningitis case patients
in this analysis. Median age was 8 years (ranging from 0
to 79 years): 230 (42%) case patients were younger than 2
years of age (35% were younger than 1 year), and 6%
were adults >50 years. Males comprised 64% (137/216) of
cases in children <2 years, and 64% (354/548) overall.
Underlying medical conditions were present in 141
(25.7%) patients and included: alcoholism (19), hyperten-
sion (16), repetition IVAS (12), chronic otitis media (12),
diabetes (8), asthma (7), sickle cell anemia (6), and HIV
infection (4). The presence of underlying disease was not
associated with infection with penicillin-resistant pneu-
mococci (Odds Ratio [OR] 0.6; 95% CI, 0.3-1.1]. Thirty-
four patients had a history of prior hospitalization.
Thirty-one patients had a history of meningitis before the
episode included in the present study.
The median duration of symptoms before hospital
admission was 2 days (mean: 2.9 range: 0 to 30 days). On
presentation, 34% (181/533) of the patients had a history
of generalized or focal seizures and 257 (48%) patients had
altered mental status; of these, 32% (83/257) were in
coma. The initial CSF parameters for these patients
showed a mean leukocyte (WBC) count of 4,193/mm
3
(range 0 to 10,000). The mean protein and glucose con-
centrations were 357.3 and 26.2 mg/dl, respectively. Two
hundred and thirty-five (42.8%) patients were admitted in
ICU.
Of the 548 pneumococcal isolates from these patients,
median MIC (MIC50) for penicillin was 0.03 μg/mL, 92
(17%) had MIC > 0.06 μg/mL and of these, only 3 were
highly resistant (MIC >1.0 μg/mL); 63 (68%) of 92 peni-
cillin-resistant pneumococci were isolated from children
<2 years. The proportion of isolates resistant to penicillin
ranged from 13 to 19% over the 10-year period, without
evidence of an increasing trend (c
2 for trend, p = 0.14)
(Table 1). Three isolates with high-level penicillin resis-
tance demonstrated intermediate resistance to cefotax-
ime. All isolates were susceptible to vancomycin, and 1%
were resistant to chloramphenicol.
Serotypes included in the 10-valent and 13-valent
pneumococcal conjugate vaccine accounted for 271
(49%) and 371 (68%) of 548 isolates from meningitis
cases, respectively, and 80 (87%) versus 87 (95%) of 92
penicillin-resistant isolates (Figure 1). All three highly
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children <2 years, 152 (70%) and 120 (79%) of 216 iso-
lates were serotypes included in the 10-valent or 13-
valent vaccine, respectively.
During the study period, we observed significantly
declines in the proportion of pneumococcal meningitis
cases treated initially with ampicillin (including 47 patients
treated with ampicillin and chloramphenicol and few
patients treatedwith penicillin G, c
2 for trend = 155.7, p <
0.0001). Ceftriaxone alone became the first-line treatment
for suspected bacterial meningitis, with vancomycin use
rising and falling depending upon concerns about resis-
tance to ceftriaxone (Figure 2). Systematic corticosteroids
were administered on the day of admission to 412 (75%)
of the patients. Most case patients received at least one
antibiotic on the day of admission to which their isolate
was susceptible (Table 1).
The overall case-fatality among hospitalized patients
with pneumococcal meningitis was 37%: 57 patients (28%
of deaths) died within 24 hours of admission, 55 (27%)
died between 24 and 48 hours of admission, and a total
of 91 patients (45%) died beyond 48 hours after hospital
admission. Table 1 shows case-fatality proportions for
meningitis cases stratified by age and time period. Case-
fatality was highest during the first three years of the
study, when empiric treatment for suspected bacterial
meningitis included ampicillin (with or without chloram-
phenicol). However, 526 (96%) of 548 case patients
received an initial antibiotic regimen to which their
pneumococcal isolate was susceptible; only 22 (4%) initi-
ally received discordant therapy and of these, antibiotic
therapy was changed within 48 hours of admission for 14
(64% of 22) patients. Children <5 years with penicillin-
resistant infections tended to have longer duration of
symptoms (median, 3 days) prior to hospitalization than
those with penicillin-susceptible isolates (median, 2
days), although differences were not significant (p =
0.055). Among 7 patients with penicillin-resistant pneu-
mococci who received discordant therapy, 4 died; 3
within 36 hours of admission and one patient 11 days
after admission. One of the three patients who recovered
h a ds e q u e l a ea td i s c h a r g e .A m o n gt h e1 0p a t i e n t sw h o
received discordant therapy and died, 6 died before 36
hours of admission; and 50% (5/10) were younger than 1
year old. Among 332 patients who received a neurologi-
cal evaluation prior to discharge, 120 (36%) had a neuro-
logical deficit. The median duration of hospitalization
was 15 days (range 3 to 90).
Table 1 Case fatality for confirmed pneumococcal meningitis by period (defined by empiric antibiotic therapy)
Characteristic Time period
a Total
Dec 1995–Nov 1998 Dec 1998–Nov 2002 Dec 2002–Nov 2005
N = 209 N = 220 N = 119
Cases Deaths (%
CFR)
Cases Deaths (%
CFR)
Cases Deaths (%
CFR)
Cases Deaths (%
CFR)
Age category
<30 days 4 3 (75.0) 1 1 (100) 0 – 5 4 (80)
30-364 days 76 53 (69.7) 86 42 (48.8) 22 10 (45.4) 184 105 (57.1)
1-4 years 23 13 (56.5) 19 6 (31.6) 13 8 (61.5) 55 27 (49.1)
5-14 years 38 2 (5.3) 39 6 (15.4) 21 2 (9.5) 98 10 (10.2)
15-49 years 56 18 (32.1) 65 11 (16.9) 46 10 (21.7) 167 39 (23.3)
50 years or older 12 7 (58.3) 10 3 (30) 17 8 (47.1) 39 18 (46.1)
Initial antibiotic therapy
Ampicillin or penicillin
b 124 46 (37.1) 40 6 (15.0) 5 0 (0) 169 52 (30.8)
Ceftriaxone 68 37 (54.4) 148 50 (33.7) 108 37 (34.3) 324 124 (38.3)
Ceftriaxone + Vancomycin 1 0 (0) 20 5 (25) 1 0 (0) 22 5 (22.7)
Other/Unknown 16 12 (75) 12 9 (75) 5 1 (20) 33 22 (66.7)
Discordant therapy
c
Yes 14 7 (50) 7 3 (42.9) 1 0 (0) 22 10 (45.5)
No 195 90 (46.2) 213 66 (30.9) 118 38 (32.2) 526 193 (36.7)
Pneumococcal isolate resistant to
penicillin
d
29 17 (58.6) 37 18 (48.6) 23 9 (39.1) 92 44 (47.8)
a Study period was divided into three periods for the purposes of this analysis: empiric therapy containing a penicillin (December 1995-November 1998),
transition period (December 1998-November 2002) and empiric therapy with ceftriaxone (December 2002-November 2005).
b Includes regimens with ampicillin in combination with chloramphenicol or an aminoglycoside. A small proportion of patients received crystalline penicillin G in
place of ampicillin.
c Antibiotic therapy was defined as discordant when patients did not receive a b-lactam antibiotic for which the S. pneumoniae isolate was susceptible during the
initial 24 hours of hospitalization.
d Defined as penicillin MIC >0.06 μg/ml for a pneumococcal isolate from a patient with meningitis.
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and patients 50 years and older had the highest propor-
tions of case-fatality (Table 2). Female patients had a
higher case-fatality (42%) than male patients (34%), both
among patients younger than two years old (49 of 79
females [62%] versus 74 of 137 males [54%] died), and
among patients two years or older (32 of 115 females
[28%] versus 48 of 217 males [22%]). Patients who died
had a significant lower blood leukocyte count, lower
CSF leukocyte count and higher protein levels in CSF
than survivors, but similar duration of symptoms prior
to hospitalization (p = 0.5). Altered mental status upon
admission and seizures prior to admission were asso-
ciated with death. Underlying illness (presence of a
chronic illness) was inversely associated with case-fatal-
ity in univariate analyses.
After adjusting for age group, penicillin-resistant pneu-
mococcal meningitis cases had higher case-fatality rates
than cases caused by penicillin-susceptible organisms.
There were no significant differences in mean leukocyte
count, protein or glucose concentrations in CSF at
admission comparing patients with penicillin-resistant
versus and penicillin-susceptible isolates. In multivariate
analyses, risk factors for case-fatality were extremes of
age, coma on admission, CSF protein >300 mg/dl, blood
leukocyte count <15,000 cells/mm
3 and penicillin resis-
tance (MIC>0.06 μg/mL) (Table 2). For each log2
increase in MIC, we observed a 20% increase in case-
fatality (adjusted HR 1.20, 95% CI 1.06 to 1.36, p <
0.005). Compared to patients with pneumococcal isolates
with MIC ≤ 0.03 μg/mL, those whose isolates had MICs
of 0.06 or 0.12 μg/mL had nonsignificantly higher case-
fatality (adjusted HR 1.40, 95% CI 0.89 to 2.19) and those
whose isolates had MICs ≥ 0.25 μg/mL had significantly
higher mortality (adjusted HR 2.65, 95% CI 1.38 to 5.05).
Infection with pneumococcal serotype 14, the most fre-
quent serotype among penicillin-resistant isolates, was
associated with lower case-fatality after adjusting for age
and penicillin-resistance (Table 2). In separate multivari-
able models for patients <15 years versus patients ≥ 15
years of age, mortality was significantly higher among
patients < 15 years with penicillin-resistant isolates
Table 2 Risk factors for death during hospitalization from pneumococcal meningitis in Salvador, Brazil
Characteristics No. of
cases
No. deaths
(%)
Univariate Hazard Ratio (95%
CI)
Adjusted Hazard Ratio (95% CI)
a
Age category
<1 years 189 109 (58) 2.58 (1.90-3.50) 2.61 (1.54-4.43)
1-4 years 55 27 (49) 2.20 (1.49-3.24) 3.14 (1.57-6.29)
5-14 years 98 10 (10) 0.46 (0.24-0.88) 0.67 (0.28-1.56)
15-50 years 170 38 (23) 1.0 1.0
>50 years 33 18 (55) 2.44 (1.61-3.71) 2.14 (1.11-4.10)
Female 193 81 (42) 1.21 (0.97-1.51)
Underlying condition
b 141 42 (30) 0.75 (0.57-1.00)
Clinical presentation
Seizures prior to hospitalization 181 83 (46) 1.40 (1.13-1.74)
Coma on admission 83 47 (57) 1.69 (1.34-2.12) 2.55 (1.66-3.91)
Laboratory values
Blood leukocyte count < 15,000 cells/μL 200 89 (44) 1.36 (1.09-1.69) 3.53 (2.18-5.71)
CSF protein >300 mg/dL
c 308 125 (41) 1.36 (1.07-1.73) 1.88 (1.12-3.17)
Pneumococcal isolate resistant to
penicillin
d
93 45 (48) 1.39 (1.09-1.78) 1.62 (1.08-2.43)
Serotype 14 74 36 (49) 1.38 (1.06-1.80) 0.52 (0.29-0.91)
Treatment
Discordant therapy
e 22 10 (45) 1.24 (0.77-1.98)
Systemic corticosteroids
f 412/539 159 (39) 1.25 (0.94-1.68)
ICU admission 235/548 130 (55) 2.37 (1.88-2.99)
NOTE: CI, confidence interval; MIC, minimal inhibitory concentration; ICU, intensive care unit.
a Hazard ratios and 95% confidence intervals from multivariable Cox proportional hazards model including age category, presence of coma, CSF protein >300
mg/dL, blood leukocyte count <15,000 cells/μL, penicillin MIC >0.06 μg/ml and serotype 14.
b Includes HIV infection, diabetes mellitus, asplenia, sickle cell disease, congestive heart failure, other disorders associated with immunodepression and recurrent
meningitis.
c CSF protein measured at time of admission; data missing for 12 case patients.
d Defined as penicillin MIC >0.06 μg/ml for a pneumococcal isolate from a patient with meningitis.
e Antibiotic therapy was defined as discordant when patients did not receive any antibiotic to which the S. pneumoniae isolate was susceptible during the initial
24 hours of hospitalization.
f Defined as initiation of corticosteroid therapy within 48 hours of admission; information missing for 9 case patients.
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ciation did not reach statistical significance among older
patients (adjusted HR 1.22, 95% CI 0.96 to 1.56). Corti-
costeroid use and discordant antibiotic therapy were not
significant risk factors for death when included in the
model. Excluding from the model 55 patients who died
within 24 hours of hospitalization or 13 patients for
whom initial antibiotic therapy was unknown did not
alter the findings significantly. Penicillin-resistance
remained associated with higher case-fatality when analy-
sis was restricted to patients whose initial therapy
included ceftriaxone (Table 3).
Discussion
In this large series of pneumococcal meningitis cases pro-
spectively identified over a ten year period of active sur-
veillance at a public infectious disease referral hospital in
Brazil, we found an association between case-fatality and
penicillin resistance among pneumococcal meningitis
cases. This association is unlikely to be due to decreased
sensitivity to penicillin alone, because few patients with
penicillin resistant isolates received initial penicillin treat-
ment. The small number of patients who received discor-
dant therapy, or antibiotics to which their isolate was
resistant, resulted in low statistical power to detect an
independent effect of discordant therapy on outcome. In
addition, initial penicillin therapy was changed to ceftriax-
one once results of antibiotic susceptibility testing showed
that the isolate had reduced sensitivity to penicillin. Dur-
ing the study period, ceftriaxone replaced penicillin as
first-line therapy for suspected bacterial meningitis, yet we
did not find that initial treatment with ceftriaxone reduced
case-fatality. Young children, with the highest case-fatality,
were more likely to have penicillin-resistant pneumococcal
isolates. Following this initial finding, the hospital pur-
chased limited amounts of cefriaxone for empiric treat-
ment of young children with suspected bacterial
meningitis. Because the majority of deaths occurred soon
after admission, initial ceftriaxone therapy may not signifi-
cantly have improved survival; patients with penicillin
resistant pneumococcal infections may have presented
with more severe disease. Alternatively, although we con-
trolled for age in the analysis, young age may still have
confounded the association between case-fatality and
infection with penicillin-resistant pneumococci.
Prior to the availability of low cost third-generation
cephalosporins, developing countries faced a dilemma in
dealing with the problem of rising penicillin resistance
among S. pneumoniae: implement empiric therapy with
cephalosporins at substantial increased cost to the health
system, or maintain empiric therapy with penicillin (and
chloramphenicol) [6]. Treatment of resistant pneumococ-
cal infections with chloramphenicol and penicillin risked
treatment failure and adverse outcomes, even at high con-
centrations of penicillin [16-18]. Pharmacokinetic studies
indicated poor penetration of penicillin into cerebrospinal
fluid, which resulted in concentrations below those
required for sterilization of CSF for pneumococcal isolates
with MIC > 0.06 μg/mL [19]. In addition, failure of chlor-
amphenicol treatment has been described in patients
Table 3 Adjusted hazard ratios for death during hospitalization from final regression model stratified according to
whether or not patient received initial ceftriaxone therapy.
Characteristics Initial ceftriaxone therapy (N = 247) Initial antibiotic other than ceftriaxone (N = 164)
Adjusted Hazard Ratio (95% CI)
a
Age category
<1 years 3.44 (1.58-7.48) 2.55 (1.21-5.39)
b
1-4 years 4.16 (1.67-10.38)
5-14 years 2.61 (0.86-7.94) 1.0
b
15-50 years 1.0
>50 years 1.72 (0.63-4.68) 2.61 (1.07-6.39)
Clinical presentation
Coma on admission 2.42 (1.36-4.30) 2.82 (1.43-5.56)
Laboratory values
Blood leukocyte count < 15,000 cells/μL 4.38 (2.33-8.25) 2.68 (1.26-5.69)
CSF protein >300 mg/dL
c 2.72 (1.44-5.14) 1.19 (0.45-3.15)
Pneumococcal isolate resistant to penicillin
d 1.68 (1.02-2.76) 1.37 (0.65-2.89)
Serotype 14 0.48 (0.25-0.90) 0.52 (0.14-1.93)
NOTE: CI, confidence interval; MIC, minimal inhibitory concentration.
a Hazard ratios and 95% confidence intervals from multivariable Cox proportional hazards model including age category, presence of coma, CSF protein >300
mg/dL, blood leukocyte count <15,000 cells/μL, penicillin MIC >0.06 μg/ml and serotype 14.
b For patients who received initial antibiotic therapy other than ceftriaxone, age categories for <1 and 1-4 years, and for 5-14 and 15-50 years were combined.
c CSF protein measured at time of admission; data missing for 12 case patients.
d Defined as penicillin MIC >0.06 μg/ml for a pneumococcal isolate from a patient with meningitis.
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tings in which antimicrobial susceptibility testing was
available, patients with penicillin-resistant pneumococcal
infections could receive appropriate treatment after results
of susceptibility testing were known. In practice, this strat-
egy leads to delay in administration of appropriate treat-
ment, which is associated with delayed sterilization of CSF
and worse outcomes [20]. Delays in diagnosis have also
been associated with poor outcomes in bacterial meningi-
tis [21] and likely contributed to the high case-fatality in
our setting. An alternative strategy used successfully in
Papua New Guinea initiated empiric therapy with ceftriax-
one and switched to a less expensive antibiotic (chloram-
phenicol) once isolates were identified as fully susceptible
[22]. In our setting, switching from ceftriaxone to penicil-
lin for penicillin-sensitive isolates was uncommon due to a
preference for administration of ceftriaxone at 12-hour
intervals versus 4- or 6-hour intervals for penicillin G or
ampicillin, respectively.
Our findings underscore the importance of antimicro-
bial susceptibility testing, both to guide treatment as well
as to provide local data on prevalence of antimicrobial
resistance. Following identification in 1996 of a cluster of
penicillin-resistant pneumococcal meningitis cases with
high case-fatality [11], the infectious diseases hospital
increased its purchase of ceftriaxone, at the time ten times
the cost of penicillin therapy. Initially, ceftriaxone was
prioritized for treatment of children due to higher propor-
tions of penicillin resistant pneumococcal meningitis
among children. One of the objectives of monitoring out-
comes of pneumococcal meningitis cases at the study hos-
pital was to justify the increased expense of empiric
ceftriaxone therapy. However, despite evidence of increas-
ing resistance to penicillin from several settings in Brazil
[23,24], the Brazilian Ministry of Health did not change
recommended first-line therapy for suspected bacterial
meningitis or pneumococcal meningitis to ceftriaxone due
to concerns about costs and risk of stock-outs of the more
expensive antibiotic. The prevalence of penicillin resistant
infections was considered low enough not to warrant revi-
sion of national recommendations, acknowledging the
need for rapid identification of resistant infections and
local decisions regarding choice of empiric therapy. One
result of the WHO recommendations was that Ministries
of Health in developing countries were left to make their
own decisions regarding levels of penicillin resistance con-
sidered acceptable for use of penicillin as first-line therapy
for pneumococcal meningitis [5]. However, few developing
countries had representative data on antimicrobial sus-
ceptibility patterns among invasive pneumococcal isolates.
The 2008 revision of Clinical and Laboratory Standards
Institute susceptibility breakpoints for Streptococcus
pneumoniae brought laboratory definitions in line with
treatment recommendations [15]. Prior to the 2008
revision, invasive pneumococcal isolates with penicillin
MIC > 0.06 μg/mL were classified as penicillin-nonsus-
ceptible: penicillin MIC from 0.1 to 1.0 μg/mL was classi-
fied as intermediate and MIC > 1.0 μg/ml as resistant
[25]. Observational studies suggested that high dose peni-
cillin therapy was effective for treatment of invasive
pneumococcal infections outside the central nervous sys-
tem [26]. Together with the limited clinical data on out-
comes of penicillin-resistant pneumococcal meningitis
treated with penicillin, this classification created uncer-
tainty regarding the treatment of pneumococcal meningi-
tis with intermediate resistance to penicillin. The low
prevalence of pneumococcal isolates with MIC > 1.0 μg/
mL in studies throughout Brazil [27] was considered by
the Brazilian Ministry of Health not to justify replace-
ment of penicillin as first-line therapy for suspected bac-
terial meningitis.
Additional data are needed on potential benefits and
risks of adjunct dexamethasone therapy for pneumococcal
meningitis in developing countries, especially in settings
where antibiotic resistance is prevalent. In a 2010
Cochrane review, adjunctive treatment with dexametha-
sone was associated with lower case-fatality in pneumo-
coccal meningitis and lower incidence of severe hearing
loss in children with meningitis due to Haemophilus influ-
enzae, but no benefit of dexamethasone treatment was
found for bacterial meninigitis patients in low-income
countries [28]. One randomized, controlled trial con-
ducted in six Latin American countries showed that treat-
ment with oral glycerol reduced neurological sequellae in
children with meningitis, suggesting alternatives to dexa-
methasone treatment [29]. Brazilian Ministry of Health
guidelines for treatment of bacterial meningitis provide no
recommendation regarding use of corticosteroids [12]. In
our analysis, we observed no confounding effect of adjunct
corticosteroid therapy on the association between case-
fatality and penicillin resistance. Although the use of ster-
oids was frequent among patients with pneumococcal
meningitis, dexamethaxone was not used systematically
and was indicated according to physician preference.
Therefore, the lack of association between initial dexa-
methasone therapy and outcome of pneumococcal menin-
gitis in this series should be interpreted with caution, as
with other observational studies [30]. Concern has been
expressed that treatment with steroids would reduce the
vancomycin concentrations in cerebrospinal fluid in adults
and therapeutic failures have been described [30]. In our
hospital, the pneumococcal meningitis cases treated with
ceftriaxone and vancomycin were mainly pediatric; most
also received dexamethaxone.
The availability of low cost ceftriaxone therapy in
developing countries makes the findings of this study less
relevant for decisions regarding choice of empiric therapy
for suspected bacterial meningitis or pneumococcal
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Page 8 of 10meningitis. However, surveys of essential medicines in
developing countries show wide variability in the actual
price of ceftriaxone and its availability in public hospitals,
suggesting that penicillins may still be used for first-line
treatment in some countries [10]. Pneumococcal resis-
tance to cephalosporins needs to be monitored [31,32],
although cefotaxime nonsusceptibility has not been asso-
ciated with increased mortality of pneumococcal menin-
gitis treated with cefotaxime [33-35].
The high mortality and burden of pneumococcal menin-
gitis among Brazilian children were among the principal
reasons for the Brazilian Ministry of Health’sd e c i s i o nt o
introduce pneumococcal conjugate vaccine in the routine
infant immunization schedule in 2010. Brazil was one of
the first countries to introduce a novel pneumococcal con-
jugate vaccine including 10 serotypes into its national
immunization program. Based on data from this surveil-
lance as well as laboratory-based surveillance in Brazil
[36], the 10-valent vaccine formulation includes the most
prevalent serotypes in pneumococcal meningitis cases in
young children, including those serotypes accounting for
the majority of penicillin-resistant isolates. Because the 10-
valent vaccine was licensed based on immunogenicity data,
its effectiveness against invasive pneumococcal disease due
to vaccine serotypes, as well as its effect on potentially
cross-reactive serotypes (such as 6A and 19A) needs to be
determined. Antibiotic use may exert selective pressure
leading to expansion of resistant clones with non-vaccine
type capsular polysaccharides. Continued surveillance fol-
lowing vaccine introduction is warranted to monitor anti-
biotic resistance among invasive pneumococcal infections
to guide treatment decisions.
Conclusions
In this observational study of pneumococcal meningitis
outcomes, patients infected with pneumococci with
reduced susceptibility to penicillin had higher case-fatal-
ity than patients with penicillin-sensitive isolates, even
when initial antibiotic therapy included ceftriaxone.
A p p r o p r i a t ea n t i b i o t i ct h e r a p ym a yn o th a v eb e e n
initiated early enough in the course of infection to pre-
vent death. Although ceftriaxone has become more
available in developing countries since the time of this
study, these findings are relevant where penicillin anti-
biotics are still used due to lack of information about
penicillin resistance or limited availability of ceftriaxone.
These findings support the use of third generation
cephalosporin antibiotics for treatment of suspected
pneumococcal meningitis even at low prevalence of
pneumococcal resistance to penicillins.
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